PZPeng Zhang

Peng Zhang

*This is an algorithmically generated author record based on publicly available information.

Peng Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Tai Xie

    CIMS Global, Somerset, NJ

    2 shared publications
  • Weichung Joe Shih

    Biostatistics and Epidemiology Department, School of Public Health Rutgers University Piscataway New Jersey USA

    2 shared publications
  • Chuxiong Pan

    Department of Anesthesia Beijing Tongren Hospital Capital Medical University Beijing China

    1 shared publication
  • Dan Kang

    Department of Otolaryngology Head and Neck Surgery Beijing TongRen Hospital Capital Medical University Beijing China

    1 shared publication
  • Jingying Ye

    Department of Otolaryngology-Head Neck Surgery and Sleep Medicine Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China

    1 shared publication
  • K. K. Gordon Lan

    Department of Biostatistics and Epidemiology, School of Public Health, Rutgers University, The State University of New Jersey, Piscataway, NJ

    1 shared publication

Latest Publications

  • Open Access

    Dynamic Monitoring of Ongoing Clinical Trials

    by Tai Xie, Peng Zhang, Weichung Joe Shih, Yue Tu, K. K. Gordon Lan

    In late 2019, the US FDA updated a new Guidance for Industry on Adaptive Designs for Clinical Trials of Drugs and Biologics. The guideline encourages developing and implementing innovative trial designs for future clinical trials. Group sequential, sample size re-estimation, and adaptive group sequential procedures have been very useful for improving the efficiency of conducting trials for decades. However, they face some challenges in operational aspects which limited their potentials. In this paper we introduce a procedure that addresses these issues. Our proposed procedure has the capability of providing anytime accessibility of the whole up-to-date data history. The procedure is largely built on the proven adaptive group sequential design theories and combined with advanced eClinical technologies in trial management to elevate the trial design and monitoring to a more dynamic level. The construct of a new trial monitoring screen is illustrated with real trial examples. The advantages of anytime accessibility of data and the monitoring a trial with the whole data history and trend are delineated. Data monitoring committees, sponsors and regulatory authorities are important stakeholders in the discussion of how future clinical trials should be monitored with respect to timing and frequency.


  • Open Access

    Remdesivir is Effective for Moderately Severe Patients: A Re-Analysis of the First Double-Blind, Placebo-Controlled, Randomized Trial on Remdesivir for Treatment of Severe COVID-19 Patients Conducted in Wuhan City

    by Weichung J Shih, Xin Shen, Peng Zhang, Tai Xie

    Introduction: The first clinical trial on remdesivir for treatment of severe COVID-19 conducted in China was terminated prematurely due to limited patient enrollment, which rendered the findings inconclusive. We re-analyzed the efficacy with a statistically more powerful and clinically meaningful method based on published data using the 6-point ordinal scale of patient's disease severity. Methods: We defined response as patient's point reached, either 2 (hospitalized, no requirement for supplementary oxygen therapy) or 1 (discharged or met discharge criterion), and then analyzed with logistic regression with baseline score, day of assessment, treatment group, baseline by treatment interaction, and day by treatment interaction as covariates. The binary endpoint was supported by the recent FDA's guidance on COVID-19. Results: Eighty-two percent (82%) of the patients were in the disease severity point=3 (hospitalized, required supplemental oxygen (but not NIV/HFNC)) - the moderately severe category. The response rate was 85% for remdesivir-treated patients with baseline disease point=3 versus 70% response rate for likewise placebo-treated patients on Day 28 (OR=2.38, P=0.0012). On Day 14, the response rate for these patients was 43% for remdesivir versus 33% for placebo (OR=1.53, P=0.0022). For patients with baseline disease point=4 (critically severe category), no similar comparisons were statistically significant. Conclusion and Discussion: The Chinese trial was not really under-powered as previously perceived or portrayed by many opinions. This result supports the preliminary findings of ACTT that remdesivir is effective for patients who were not critically severe. This result also suggests that remdesivir should be given to hospitalized COVID-19 patients as soon as possible. There is no race difference in the treatment effect.


  • The Role of Obstruction Length and Height in Predicting Outcome of Velopharyngeal Surgery

    by Peng Zhang, Jingying Ye, Chuxiong Pan, Nian Sun, Dan Kang

    Objective: To measure obstruction length and height using drug‐induced sleep endoscopy (DISE) in obstructive sleep apnea (OSA) patients and to evaluate their association with outcomes of velopharyngeal surgery.Study Design: Prospective cohort study.Setting: University medical center.Methods: Forty‐three consecutive patients with OSA were evaluated by DISE using dexmedetomidine. The 2 new parameters, obstruction length (defined as the distance from the most superior point of the collapse to the most inferior point of the collapse) and obstruction height (the distance from the posterior border of the nasal septum to the most proximal point of the collapse), were measured by both DISE and a pressure transducer catheter method before surgery. All of the patients received velopharyngeal surgery, including revised uvulopalatopharyngoplasty with uvula preservation and transpalatal advancement pharyngoplasty. We followed up with all of the patients using polysomnography at least 3 months after surgery.Results: Twenty‐six (60.5%) patients were responders, and 17 (39.5%) were nonresponders. The mean obstruction length and obstruction height were 1.3 ± 0.5 cm (range, 0.4‐2.2 cm) and 3.4 ± 0.9 cm (range, 1.1‐5.0 cm), respectively. Nonresponders had a longer obstruction length and a shorter obstruction value. Multivariate logistic regression analysis revealed that obstruction length >1.4 cm (odds ratio [OR], 0.21; 95% confidence interval [CI], 0.04‐0.98; P =. 048) and obstruction height ≥3.2 cm (OR, 9.35; 95% CI, 1.79‐48.80; P =. 008) were the only independent predictors of velopharyngeal surgery success.Conclusions: Accurate measurement of obstruction length and height can be performed with both DISE and a pressure transducer catheter method. The 2 parameters can predict the outcome of velopharyngeal surgery.